I'll be giving an SBGrid webinar next week:
TITAN: Getting the most from NMR titration experiments with two-dimensional lineshape analysis
10 January, 12pm EST/5pm UK/6pm CET
More info and registration: https://sbgrid.org/webinars/
I'll be giving an SBGrid webinar next week:
TITAN: Getting the most from NMR titration experiments with two-dimensional lineshape analysis
10 January, 12pm EST/5pm UK/6pm CET
More info and registration: https://sbgrid.org/webinars/
The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality with the promise to tame disease-relevant proteins in ways that are difficult or impossible to tackle with other strategies. While we move into the third decade of TPD, multiple degrader drugs have entered the stage of the clinic and many more are expected to follow. In this review, we provide an update on the most recent advances in the field of targeted degradation with insights into possible clinical implications for cancer prevention and treatment.
In about 2003 we bought a heavily used #Concept2 #rowing machine from a community gym for, I think, $150. It is a Model B that was manufactured in 1992.
Concept2 STILL provides COMPLETE #SUPPORT AND REPLACEMENT #PARTS for a 30 year old rowing machine. They still sell upgrades to the electronics. They have never end-of-lifed it. They also provide complete support for even older Model A machines.
I have almost total confidence that that will not be the case for your #Peloton, etc.
Nice and concise #review about the different #methods to increase effective molecular weight of #proteins <100 kDa through target protein binding or target protein fusion (#nanobody and symmetric #scaffolds) enabling structure determination with #cryoEM @strucbio
https://www.sciencedirect.com/science/article/pii/S2665928X22000290
Excited to showcase our latest work by postdoc @[email protected] @[email protected] @[email protected] & @[email protected] on covalently recruiting E2 ubiquitin conjugating enzyme UBE2D for targeted protein degradation applications!! Also thanks to @[email protected]! https://www.biorxiv.org/content/10.1101/2022.12.19.520812v1
🐦🔗: https://twitter.com/DanNomura/status/1605188206021865472
Final issue of our 40th #anniversary year!
Featured:
#LUBAC linear #ubiquitin signaling on #mitochondria
#Calnexin’s sugar-free taste in #lipid #bilayer
#Mitophagy receptors doubling in #pexophagy
#Cadherin-mediated #adhesion control (on the cover by Liang, Buckley et al)
...and more:
https://www.embopress.org/toc/14602075/2022/41/24